LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Uždarymo kaina

30.04 0.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.54

Max

30.38

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-30M -30M
Pardavimai	-26M 77M
Pelno marža	-38.823
Darbuotojai	524
EBITDA	-12M -8M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+118.87% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-114M 1.5B
Ankstesnė atidarymo kaina	29.54
Ankstesnė uždarymo kaina	30.04

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

27.895 / 30.16 Palaikymas ir pasipriešinimas

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-18 22:51; UTC

Uždarbis

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

2026-03-18 21:40; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

2026-03-18 20:31; UTC

Uždarbis

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

2026-03-18 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

2026-03-18 23:31; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery -- Market Talk

2026-03-18 22:49; UTC

Rinkos pokalbiai

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

2026-03-18 22:41; UTC

Rinkos pokalbiai

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

2026-03-18 22:36; UTC

Uždarbis

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

2026-03-18 22:24; UTC

Uždarbis

AIA Group Announces New Share Buyback of $1.7B >1299.HK

2026-03-18 22:23; UTC

Uždarbis

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

2026-03-18 22:23; UTC

Uždarbis

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

2026-03-18 21:58; UTC

Uždarbis

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

2026-03-18 21:55; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-03-18 21:55; UTC

Rinkos pokalbiai

Uždarbis

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

2026-03-18 21:40; UTC

Rinkos pokalbiai

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

2026-03-18 21:16; UTC

Rinkos pokalbiai

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

2026-03-18 21:00; UTC

Svarbiausios naujienos

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

2026-03-18 20:58; UTC

Uždarbis

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

2026-03-18 20:41; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:29; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:25; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:17; UTC

Uždarbis

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

2026-03-18 20:14; UTC

Rinkos pokalbiai

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

2026-03-18 20:09; UTC

Uždarbis

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

2026-03-18 20:07; UTC

Uždarbis

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

2026-03-18 20:06; UTC

Uždarbis

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology Sees 3Q Gross Margin About 81% >MU

2026-03-18 20:03; UTC

Uždarbis

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

118.87% į viršų

12 mėnesių prognozė

Vidutinis 65.75 USD 118.87%

Aukščiausias 100 USD

Žemiausias 38 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

27.895 / 30.16Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.